MOPC-315 / MOPC-315-luc Orthotopic Mouse Model Service for Multiple Myeloma (MM)

The MOPC-315 / MOPC-315-luc orthotopic mouse model for multiple myeloma engrafts a mineral oil-induced BALB/c plasmacytoma into the bone marrow compartment of immunocompetent hosts, combining decades of idiotype-immunology pedigree with modern bioluminescence tracking of marrow disease and bone destruction. Dedicated exclusively to preclinical oncology, Alfa Cytology delivers this syngeneic platform end to end: authenticated MOPC-315 / MOPC-315-luc cell supply, bone marrow-homing tail-vein inoculation into BALB/c mice, scheduled imaging paired with idiotype IgA ELISA, and terminal microCT-supported bone analysis.

Overview of MOPC-315 / MOPC-315-luc Orthotopic Mouse Model for Multiple Myeloma (MM)

MOPC-315 stands on the deepest historical foundation of any murine myeloma model. In the 1960s, Michael Potter at the US National Cancer Institute discovered that repeated intraperitoneal injections of mineral oil—or its defined component pristane—induce plasmacytomas in BALB/c mice, a strain rendered susceptible by hypomorphic alleles of p16 and Frap, and the MOPC (Mineral Oil-induced Plasmacytoma of Potter) panel he single-handedly created transformed antibody research. MOPC-315 is one of that panel’s most famous members: a B-cell plasmacytoma that secretes an IgAλ2 myeloma protein remarkable for binding dinitrophenyl and trinitrophenyl haptens, making it an early workhorse of antibody structure and idiotype research. Like most peritoneal plasmacytomas, it carries a Myc-activating Igh-Myc translocation, and it is strikingly glucocorticoid-sensitive—killed by as little as 10 nM dexamethasone. The classical line grows in suspension and requires disciplined density control, since cultures allowed above roughly 10⁶ cells per milliliter die off rapidly.

Fig 1. Subcutaneous MOPC-315 plasmacytoma model comparing empty-vector (MOPCpEF) versus VEGF-overexpressing (MOPCSVm) cells in immune-competent BALB/c versus BALB/c nude mice, showing that MOPCSVm tumors grew faster in BALB/c but were rejected in nude mice via irradiation/adoptive splenocyte transfer experiments, with tumor volume curves tracking growth over 25 days. (Kim, Byung-Gyu, et al., 2022)

For faithful multiple myeloma modeling, the bone marrow-homing derivative MOPC-315.BM is the orthotopic instrument of choice: generated by Hofgaard, Bogen, and colleagues through nine generations of serial intravenous autografting of marrow-derived plasma cells, it acquired exquisite bone marrow tropism, genuine osteolytic capacity, and a median survival of about one month in BALB/c recipients. Luciferase-tagged MOPC-315.BM delivered by tail-vein injection at 1 × 10⁵ cells homes to femur, tibia, and spleen, with the first bioluminescent signal detectable by day 9—earlier than the serum M315 idiotype rises above background—and progressive multifocal skeletal growth that histology confirms as tumor in marrow with osteolytic destruction of cortical bone. The line expresses the marrow-homing receptor triad CXCR4, CD44, and α4β1 (VLA-4), the latter two being direct targets of approved myeloma drugs, and it has served melphalan response validation, IL-34 and Notch bone-loss mechanism studies, eosinophil and megakaryocyte niche research, idiotype vaccination, and oncolytic virus programs—all in an immunocompetent host capable of modeling immune-tumor interactions that immunodeficient systems cannot.

Cell Line Information: MOPC-315 / MOPC-315-luc

MOPC-315’s half-century of use has left it documented from hapten-binding biochemistry to whole-animal imaging. The defining attributes are summarized below.

Our Services

A MOPC-315 / MOPC-315-luc engagement with Alfa Cytology is run as one continuous program: density-disciplined cell banking, tail-vein orthotopic inoculation of the marrow-homing subline into immunocompetent BALB/c recipients, IVIS imaging paired with M315 idiotype ELISA, dosing per the client’s regimen, and a terminal package combining skeletal microCT analysis, ex vivo organ imaging, and bone marrow immunohistochemistry.

Workflow of MOPC-315 / MOPC-315-luc Orthotopic Mouse Model Construction

Building a MOPC-315-luc orthotopic myeloma model turns a classical plasmacytoma into a quantitative bone marrow imaging system: density-controlled culture keeps the cells alive and healthy, tail-vein inoculation seeds the skeleton, and dual imaging-plus-idiotype readouts chart the disease. The workflow below reflects this execution.

1. Cell Bank Verification and Expansion: MOPC-315 or MOPC-315.BM-luc stocks are authenticated and mycoplasma-tested, then expanded in EMEM-based medium with strict density discipline (1–9 × 10⁵ cells/mL), since overgrowth above ~10⁶ cells/mL triggers rapid death.
2. Luciferase Calibration (MOPC-315-luc Only): Signal output per cell is verified in vitro, and CD138⁺CD4⁺ identity of the marrow-homing line is confirmed by flow cytometry before in vivo use.
3. Mouse Preparation and Randomization: Immunocompetent BALB/c mice are acclimatized and randomized by body weight under approved protocols; no irradiation or immunodeficiency is required for syngeneic engraftment.
4. Orthotopic Tail-Vein Inoculation: 1 × 10⁵ MOPC-315.BM-luc⁺ cells in a small sterile volume are delivered via the tail vein so that plasma cells home to femoral, tibial, and shoulder marrow and to the spleen.
5. Engraftment Confirmation and Longitudinal Imaging: Whole-animal BLI after D-luciferin (150 mg/kg i.p., 10-minute delay) detects the first skeletal foci by day 9, with scheduled re-imaging tracking the emergence of new foci and growth of established ones; serum M315 idiotype IgA is measured in parallel.
6. Treatment Administration: Test agents—alkylators such as melphalan, glucocorticoids, niche-targeted antibodies, or immunotherapies—are dosed per the client’s schedule once engraftment is confirmed.
7. Surveillance and Survival Endpoint: Daily monitoring tracks body weight and neurological status; paraplegia, severe weight loss, or welfare criteria define the survival endpoint, typically around one month after inoculation.
8. Terminal Skeletal and Organ Analysis: At endpoint, femurs, tibiae, and spine are scanned by microCT or processed for H&E to quantify osteolytic lesions; spleen, liver, and other organs are imaged ex vivo, and marrow is profiled by flow cytometry and immunohistochemistry (lambda light chain) to confirm plasma cell identity and burden.

Fig 2. MOPC-315 / MOPC-315-luc orthotopic mouse model construction workflow.

Case Study-MOPC-315 / MOPC-315-luc Orthotopic Mouse Model Development

Alfa Cytology has executed preclinical programs on the MOPC-315 / MOPC-315-luc orthotopic platform for clients evaluating alkylators, glucocorticoid combinations, niche-targeting antibodies, idiotype-based vaccines, and oncolytic strategies, delivering day-9-sensitive bioluminescence growth curves, M315 idiotype biomarker data, survival analyses, and microCT-supported bone lesion quantification. Because each engagement is configured around the client’s own therapeutic hypothesis, study outlines and representative datasets are available upon request.

Why Choose Alfa Cytology?

MOPC-315 demands what many CROs lack: respect for a temperamental old line. Density-controlled culture, dual imaging-plus-idiotype readouts, and immunocompetent bone marrow surgery all sit inside Alfa Cytology’s standard execution, keeping these historically rich studies both faithful and quantitative.

• Density-disciplined MOPC-315 / MOPC-315-luc banking honoring the line’s narrow viable density window.
• Genuine bone marrow-homing subline expertise, including CD138/CD4 identity verification by flow cytometry.
• Dual burden readouts: IVIS bioluminescence (sensitive from day 9) paired with M315 idiotype IgA ELISA.
• Immunocompetent BALB/c execution preserving immune-tumor interactions that immunodeficient formats cannot model.
• Endpoint skeletal microCT and lambda-chain immunohistochemistry confirming osteolytic marrow disease.
• A dedicated team owning the study from banking through the final consolidated data package.

Contact Us

Whether the question is drug efficacy, idiotype immunity, or bone disease mechanism, Alfa Cytology can configure a MOPC-315 / MOPC-315-luc orthotopic myeloma study with the sensitivity this historic model deserves.

Contact us today to discuss study design and imaging cadence, or reach out to our team for a customized quotation.

For research use only. Not intended for any clinical use.